BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37491061)

  • 1. [WHO Histological Classification of Pituitary Tumors].
    Nishioka H
    No Shinkei Geka; 2023 Jul; 51(4):642-653. PubMed ID: 37491061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of the 2022 WHO Classification of Pituitary Tumors.
    Asa SL; Mete O; Perry A; Osamura RY
    Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version].
    Xie J; Wu ZB
    Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Histological Classification and Diagnosis of Sellar/Parasellar Tumors].
    Nishioka H
    No Shinkei Geka; 2023 Sep; 51(5):789-798. PubMed ID: 37743330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Overview of the New World Health Organization Classification of Pituitary Neuroendocrine Tumors].
    Kurosaki M
    No Shinkei Geka; 2023 Sep; 51(5):910-916. PubMed ID: 37743343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
    Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U
    Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal.
    Villa C; Baussart B; Assié G; Raverot G; Roncaroli F
    Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37068095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
    Asa SL; Mete O; Riddle ND; Perry A
    Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of the 2022 WHO Classification of Pituitary Adenomas/Pituitary Neuroendocrine Tumors: Clinical Practices, Controversies, and Perspectives.
    Wan XY; Chen J; Wang JW; Liu YC; Shu K; Lei T
    Curr Med Sci; 2022 Dec; 42(6):1111-1118. PubMed ID: 36544040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annotation of pituitary neuroendocrine tumors with genome-wide expression analysis.
    Tebani A; Jotanovic J; Hekmati N; Sivertsson Å; Gudjonsson O; Edén Engström B; Wikström J; Uhlèn M; Casar-Borota O; Pontén F
    Acta Neuropathol Commun; 2021 Nov; 9(1):181. PubMed ID: 34758873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification.
    Dottermusch M; Schüller U; Hagel C; Saeger W
    Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12870. PubMed ID: 36527335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms.
    Mete O; Wenig BM
    Head Neck Pathol; 2022 Mar; 16(1):123-142. PubMed ID: 35312985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary Neuroendocrine Tumor: Is It Benign or Malignant?
    Lee CH
    Brain Tumor Res Treat; 2023 Jul; 11(3):173-176. PubMed ID: 37550816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging of pituitary tumors: an update with the 5th WHO Classifications-part 2. Neoplasms other than PitNET and tumor-mimicking lesions.
    Tsukamoto T; Miki Y
    Jpn J Radiol; 2023 Aug; 41(8):808-829. PubMed ID: 36913010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell sequencing identifies differentiation-related markers for molecular classification and recurrence prediction of PitNET.
    Zhang Q; Yao B; Long X; Chen Z; He M; Wu Y; Qiao N; Ma Z; Ye Z; Zhang Y; Yao S; Wang Y; Cheng H; Chen H; Ye H; Wang Y; Li Y; Chen J; Zhang Z; Guo F; Zhao Y
    Cell Rep Med; 2023 Feb; 4(2):100934. PubMed ID: 36754052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary.
    Lopes MBS
    Acta Neuropathol; 2017 Oct; 134(4):521-535. PubMed ID: 28821944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
    J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newer Concepts in the Classification of Pituitary Adenomas.
    Sathyakumar R; Chacko G
    Neurol India; 2020; 68(Supplement):S7-S12. PubMed ID: 32611886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal.
    Villa C; Vasiljevic A; Jaffrain-Rea ML; Ansorge O; Asioli S; Barresi V; Chinezu L; Gardiman MP; Lania A; Lapshina AM; Poliani L; Reiniger L; Righi A; Saeger W; Soukup J; Theodoropoulou M; Uccella S; Trouillas J; Roncaroli F
    Virchows Arch; 2019 Dec; 475(6):687-692. PubMed ID: 31578606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Pituitary Carcinoids Do Not Exist: A Reappraisal in the Era of Pituitary Neuroendocrine Tumours.
    Armeni E; Alexandraki KI; Roncaroli F; Grossman AB
    Arch Med Res; 2023 Dec; 54(8):102841. PubMed ID: 37394342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.